Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for Editas Medicine (EDIT) over the last 7 years, with Q3 2025 value amounting to $90.1 million.

  • Editas Medicine's Shares Outstanding (Diluted Average) rose 922.01% to $90.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.1 million, marking a year-over-year increase of 922.01%. This contributed to the annual value of $82.3 million for FY2024, which is 838.88% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Shares Outstanding (Diluted Average) is $90.1 million, which was up 922.01% from $84.4 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Shares Outstanding (Diluted Average) registered a high of $90.1 million during Q3 2025, and its lowest value of $66.0 million during Q1 2021.
  • For the 5-year period, Editas Medicine's Shares Outstanding (Diluted Average) averaged around $75.2 million, with its median value being $71.4 million (2023).
  • As far as peak fluctuations go, Editas Medicine's Shares Outstanding (Diluted Average) skyrocketed by 64.13% in 2023, and later skyrocketed by 1888.26% in 2024.
  • Quarter analysis of 5 years shows Editas Medicine's Shares Outstanding (Diluted Average) stood at $67.6 million in 2021, then rose by 1.55% to $68.7 million in 2022, then increased by 10.63% to $76.0 million in 2023, then rose by 8.39% to $82.3 million in 2024, then increased by 9.42% to $90.1 million in 2025.
  • Its last three reported values are $90.1 million in Q3 2025, $84.4 million for Q2 2025, and $83.1 million during Q1 2025.